An antibody biopolymer conjugate showed safety, efficacy and durability compared to aflibercept in various retinal conditions, according to research presented at the virtual American Academy of Ophthalmology annual meeting.
Arshad M. Khanani, MD, MA, managing partner and director of clinical research, Sierra Eye Associates, clinical associate professor of ophthalmology, University of Nevada, reviewed his findings from the long-term multiple-dose study of antibody biopolymer conjugates (ABCs) and discussed positive clinical results of KSI-301 in wet age-related macular degeneration, diabetic
Uncategorized